Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial)
Background: Cancer-related malnutrition is still unrecognized and undertreated in clinical practice. The morphofunctional assessment of disease-related malnutrition (DRM) is a new approach that focuses on evaluating changes in body composition and function. The aim of this study is to evaluate the p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/3/522 |
| _version_ | 1797623596634341376 |
|---|---|
| author | Cristina García-García Isabel María Vegas-Aguilar Rosalía Rioja-Vázquez Isabel Cornejo-Pareja Francisco J. Tinahones José Manuel García-Almeida |
| author_facet | Cristina García-García Isabel María Vegas-Aguilar Rosalía Rioja-Vázquez Isabel Cornejo-Pareja Francisco J. Tinahones José Manuel García-Almeida |
| author_sort | Cristina García-García |
| collection | DOAJ |
| description | Background: Cancer-related malnutrition is still unrecognized and undertreated in clinical practice. The morphofunctional assessment of disease-related malnutrition (DRM) is a new approach that focuses on evaluating changes in body composition and function. The aim of this study is to evaluate the prognostic value of classic and emerging assessment of malnutrition at 12-months survival in cancer patients. Methods. We conducted a prospective study on cancer outpatients. Bioelectrical impedance with phase angle (PhA), nutritional ultrasound by rectus femoris cross-sectional area (RFCSA), hand grip strength, and “Timed Up and Go Test” (TUG) were evaluated as predictors of mortality. Results. Fifty-seven patients were included. The non-survivors had lower PhA values than the survivors (4.7° vs. 5.4°; <i>p</i> < 0.001), and we had the same results with RFCSA 2.98 cm<sup>2</sup>/m<sup>2</sup> vs. 4.27 cm<sup>2</sup>/m<sup>2</sup> (<i>p</i> = 0.03). Cut-off points were identified using the ROC (receiver operating characteristic) curves for PhA (≤5.6° cancer patients, ≤5.9° men, ≤5.3° women), RFCSA (≤4.47 cm<sup>2</sup>/m<sup>2</sup> cancer patients, ≤4.47° men, ≤2.73° women) and rectus femoris-Y-axis (RF-Y-axis; ≤1.3 cm cancer patients, ≤1.06 men, ≤1 women). In multivariate logistic regression analysis, we found that high PhA was significantly associated with a lower mortality hazard ratio (HR: 0.42 95% CI: 0.21–0.84, <i>p</i> = 0.014). Likewise, high RFCSA was associated with a decrease in mortality risk in the crude model (HR: 0.61 95% CI: 0.39–0.96, <i>p</i> = 0.031). This trend was also maintained in the adjusted models by the confounding variables. Conclusions. Low PhA and RFCSA values are significant independent predictors of mortality in cancer patients. These cut-off points are clinical data that can be used for nutritional assessment and the prediction of clinical outcomes. |
| first_indexed | 2024-03-11T09:31:08Z |
| format | Article |
| id | doaj.art-2e7f4524da6a41e79d99c9fec2b48191 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T09:31:08Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-2e7f4524da6a41e79d99c9fec2b481912023-11-16T17:38:06ZengMDPI AGNutrients2072-66432023-01-0115352210.3390/nu15030522Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial)Cristina García-García0Isabel María Vegas-Aguilar1Rosalía Rioja-Vázquez2Isabel Cornejo-Pareja3Francisco J. Tinahones4José Manuel García-Almeida5Facultad de Medicina, Universidad of Málaga, 29010 Málaga, SpainUnidad de Gestión Clínica en Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, 29010 Málaga, SpainUnidad de Gestión Clínica en Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, 29010 Málaga, SpainUnidad de Gestión Clínica en Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, 29010 Málaga, SpainFacultad de Medicina, Universidad of Málaga, 29010 Málaga, SpainFacultad de Medicina, Universidad of Málaga, 29010 Málaga, SpainBackground: Cancer-related malnutrition is still unrecognized and undertreated in clinical practice. The morphofunctional assessment of disease-related malnutrition (DRM) is a new approach that focuses on evaluating changes in body composition and function. The aim of this study is to evaluate the prognostic value of classic and emerging assessment of malnutrition at 12-months survival in cancer patients. Methods. We conducted a prospective study on cancer outpatients. Bioelectrical impedance with phase angle (PhA), nutritional ultrasound by rectus femoris cross-sectional area (RFCSA), hand grip strength, and “Timed Up and Go Test” (TUG) were evaluated as predictors of mortality. Results. Fifty-seven patients were included. The non-survivors had lower PhA values than the survivors (4.7° vs. 5.4°; <i>p</i> < 0.001), and we had the same results with RFCSA 2.98 cm<sup>2</sup>/m<sup>2</sup> vs. 4.27 cm<sup>2</sup>/m<sup>2</sup> (<i>p</i> = 0.03). Cut-off points were identified using the ROC (receiver operating characteristic) curves for PhA (≤5.6° cancer patients, ≤5.9° men, ≤5.3° women), RFCSA (≤4.47 cm<sup>2</sup>/m<sup>2</sup> cancer patients, ≤4.47° men, ≤2.73° women) and rectus femoris-Y-axis (RF-Y-axis; ≤1.3 cm cancer patients, ≤1.06 men, ≤1 women). In multivariate logistic regression analysis, we found that high PhA was significantly associated with a lower mortality hazard ratio (HR: 0.42 95% CI: 0.21–0.84, <i>p</i> = 0.014). Likewise, high RFCSA was associated with a decrease in mortality risk in the crude model (HR: 0.61 95% CI: 0.39–0.96, <i>p</i> = 0.031). This trend was also maintained in the adjusted models by the confounding variables. Conclusions. Low PhA and RFCSA values are significant independent predictors of mortality in cancer patients. These cut-off points are clinical data that can be used for nutritional assessment and the prediction of clinical outcomes.https://www.mdpi.com/2072-6643/15/3/522cancerdisease-related malnutritionbioelectrical impedancephase anglerectus femoris musclemortality |
| spellingShingle | Cristina García-García Isabel María Vegas-Aguilar Rosalía Rioja-Vázquez Isabel Cornejo-Pareja Francisco J. Tinahones José Manuel García-Almeida Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial) Nutrients cancer disease-related malnutrition bioelectrical impedance phase angle rectus femoris muscle mortality |
| title | Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial) |
| title_full | Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial) |
| title_fullStr | Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial) |
| title_full_unstemmed | Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial) |
| title_short | Rectus Femoris Muscle and Phase Angle as Prognostic Factor for 12-Month Mortality in a Longitudinal Cohort of Patients with Cancer (AnyVida Trial) |
| title_sort | rectus femoris muscle and phase angle as prognostic factor for 12 month mortality in a longitudinal cohort of patients with cancer anyvida trial |
| topic | cancer disease-related malnutrition bioelectrical impedance phase angle rectus femoris muscle mortality |
| url | https://www.mdpi.com/2072-6643/15/3/522 |
| work_keys_str_mv | AT cristinagarciagarcia rectusfemorismuscleandphaseangleasprognosticfactorfor12monthmortalityinalongitudinalcohortofpatientswithcanceranyvidatrial AT isabelmariavegasaguilar rectusfemorismuscleandphaseangleasprognosticfactorfor12monthmortalityinalongitudinalcohortofpatientswithcanceranyvidatrial AT rosaliariojavazquez rectusfemorismuscleandphaseangleasprognosticfactorfor12monthmortalityinalongitudinalcohortofpatientswithcanceranyvidatrial AT isabelcornejopareja rectusfemorismuscleandphaseangleasprognosticfactorfor12monthmortalityinalongitudinalcohortofpatientswithcanceranyvidatrial AT franciscojtinahones rectusfemorismuscleandphaseangleasprognosticfactorfor12monthmortalityinalongitudinalcohortofpatientswithcanceranyvidatrial AT josemanuelgarciaalmeida rectusfemorismuscleandphaseangleasprognosticfactorfor12monthmortalityinalongitudinalcohortofpatientswithcanceranyvidatrial |